The development of depot antipsychotics has facilitated incompatible patient’s treatment process for in terms of the course of chronic disease. Several kinds of antipsychotics with varying dosing ranges are commercially available. An interval of fifteen days to one-month period has increased the effectiveness of depot antipsychotics. One of them is haloperidol depot. Haloperidol depot, generically named as haldol decanoate has been used in abroad (Europe-US) since 1986. Medications in depot form have some advantages such as reducing drug incompatibilities, preventing relapses, reducing hospitalizations and health costs, EPS incidence of side effects is low, providing the clinician to ensure compliance to treatment, reducing psychotic symptoms and need for dose reduction, providing a steady blood level and so preventing blood level şuctuations in oral administration. Whereas the depot form is an advantage for compliance, it brings a disadvantage because of lack of possibility to wash out the administered dose if an adverse effect is observed. . In addition, they have got some disadvantages such as lack of dose şexibility and patients feeling under constant self-control. As known, one of the disadvantages of depot antipsychotics is the high rates of NMS (neuroleptic malignant syndrome). NMS is not common but can be fatal once seen. Our literature search revealed nine NMS cases with oral administration in Turkey. None of these cases of NMS were associated with haloperidol depot administration. In our case, a schizophrenia patient, who was suffering neuroleptic malignant syndrome upon the recent use of haloperidol depot was reported.